Amy Jacob

NIAID Director Anthony Fauci, MD is globally renowned for immunology research.

The FDA gave a green light to an add-on therapy for Parkinson's.

Some researchers have considered treating C. difficile with fidaxomicin.

IBS-D treatment eluxadoline is a risk for patients who do not have gallbladders.

The kind of strategies Myron Cohen, MD and team used for STDs and the gonorrhea bacterial pathogen were applied to HIV.

"ART treatment is exceptionally good at stopping transmission," said Myron Cohen, MD, Department of Infectious Disease, UNC.

Researchers question freeze-dried vs. fresh products in FMT for C. difficile.

John Kelso, MD, Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, explained the concerns researchers had of administering vaccines to patients experiencing allergic reactions to those vaccines.

Vitamin E deficiency in mothers can affect their children's risk of asthma.

Amy Scurlock, MD, Arkansas Children's Hospital, reiterated that there is more at stake beyond the medical management of food allergies.

Amy Scurlock, MD, Arkansas Children's Hospital, and team conducted a study looking at walnut oral immunotherapy in children with tree nut allergies.

Luis Salmun, MD, VP, Medical Affairs, North America, DBV Technologies, discussed results from the Viaskin Peanut study and explained the patch could be a potential treatment for children with peanut allergies.

"Not only has it shown efficacy in atopic dermatitis, but dupilumab also has shown efficacy in related atopic dermatitis conditions such as asthma and nasal polyps," said Akinlade.

Bola Akinlade, MD, MBA, Executive Director, Regeneron Pharmaceuticals, discussed the results of the dupilumab study presented at AAAAI 2017.

Jared Ditkowsky, MD, SUNY Downstate, explained the connotations surrounding the development of a potential vaccine for Chlamydia trachomatis (C. trachomatis), the infection causing chlamydia - one of the most common bacterial sexually transmitted infections in the United States.

Jared Ditkowsky, MD candidate, SUNY Downstate explained that many of the problems surrounding a potential chlamydia vaccine are immunologic in nature.

Jay Jin, MD, PhD, Mayo Clinic, shared the results from his team's case series surrounding unexpected bradycardia effect from epinephrine administration.

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), shared with MD Magazine what the main theme would be in his keynote address at the AAAAI 2017 meeting in Atlanta, GA: emerging and reemerging infections, a perpetual challenge.

Mark S. Forshag, MD, MHA, with GSK, shared some of his team's next steps in advancing asthma care specifically with trying to keep things simple for the patients and their physicians.

Mark S. Forshag, MD, MHA, GSK, spoke with MD Magazine at AAAAI 2017 in Atlanta, GA, about the importance of eosinophils in treating severe asthma.

Would carrying a rescue inhaler correlate with better asthma control? That's what Sima J. Patel, DO and her team sought to investigate.

Luz Fonacier, MD, Winthrop University Hospital, detailed the process of looking at eczema and contact dermatitis in an allergist's practice.

Katia Boven, MD, Head of Clinical Development and Global Medical Affairs, Infectious Diseases, Janssen, discussed results and impact of the SWORD clinical trial involving the investigational two-drug combination being as effective as the three or four regimens as maintenance therapy in HIV patients who have already achieved viral suppression.

Colon cancer is affecting younger populations at an alarming rate.

One team's goal at the US Military HIV research Program is to control plasma viral load in the blood to undetectable levels without the use of long-term ART.

Some doctors urge FDA to lift regulations on the so-called abortion pill.

Oral ozanimod treatment can reduce MS relapse rates.

"We've done a really good job of developing medicines to get that virus under control. I think what's sort of important for our community now is to very carefully look at what the unmet needs are," said Emu.

"Even though we have a lot of drugs, because of the resistance profile of their virus, they don't have a lot of options, so what these results mean for the most vulnerable of our patients is that they have access now to a new class of drugs," Emu concluded.